Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jincao Xiaodu Keli phase IIa trial in advanced hepatocellular carcinoma
CTR20233226Phase 2Active
- Sponsor
- Duoling Biotech
- Start
- Nov 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Jincao Xiaodu Keli in hepatocellular carcinoma (HCC), sponsored by Duoling Biotech. Started Nov 2023; status: active.
02
Drugs
Jincao Xiaodu Keli
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20233226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233226.